HomeCompareSGTX vs MO

SGTX vs MO: Dividend Comparison 2026

SGTX yields 8.90% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $44.1K in total portfolio value· pulled ahead in Year 7
10 years
SGTX
SGTX
● Live price
8.90%
Share price
$22.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36.0K
Annual income
$1,560.55
Full SGTX calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — SGTX vs MO

📍 MO pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGTXMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGTX + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGTX pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGTX
Annual income on $10K today (after 15% tax)
$756.56/yr
After 10yr DRIP, annual income (after tax)
$1,326.47/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, MO beats the other by $24,308.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGTX + MO for your $10,000?

SGTX: 50%MO: 50%
100% MO50/50100% SGTX
Portfolio after 10yr
$58.1K
Annual income
$15,859.86/yr
Blended yield
27.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

SGTX
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Altman Z
-6.6
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGTX buys
0
MO buys
0
No recent congressional trades found for SGTX or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGTXMO
Forward yield8.90%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$36.0K$80.1K
Annual income after 10y$1,560.55$30,159.17
Total dividends collected$12.3K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy

Year-by-year: SGTX vs MO ($10,000, DRIP)

YearSGTX PortfolioSGTX Income/yrMO PortfolioMO Income/yrGap
1$11,590$890.08$10,570$780.30+$1.0KSGTX
2$13,365$964.12$11,381$1,032.90+$2.0KSGTX
3$15,340$1,039.07$12,535$1,392.73+$2.8KSGTX
4$17,529$1,114.56$14,193$1,920.91+$3.3KSGTX
5$19,946$1,190.25$16,618$2,723.68+$3.3KSGTX
6$22,608$1,265.78$20,263$3,993.80+$2.3KSGTX
7← crossover$25,531$1,340.85$25,936$6,098.36$405.00MO
8$28,734$1,415.18$35,166$9,775.01$6.4KMO
9$32,233$1,488.49$51,026$16,597.78$18.8KMO
10$36,050$1,560.55$80,113$30,159.17$44.1KMO

SGTX vs MO: Complete Analysis 2026

SGTXStock

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Full SGTX Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this SGTX vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGTX vs SCHDSGTX vs JEPISGTX vs OSGTX vs KOSGTX vs MAINSGTX vs PMSGTX vs BTISGTX vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.